<DOC>
	<DOCNO>NCT00530452</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy 3 load maintenance dose level CG100649 administer 21 day treatment osteoarthritis pain .</brief_summary>
	<brief_title>Phase II Study CG100649 Primary Osteoarthritis Male Subjects</brief_title>
	<detailed_description>This double-blind , placebo-controlled study . Subjects discontinue current medication 5-14 day prior randomization . Paracetamol ( acetaminophen ; ≤2 gm/day ) may use breakthrough pain . Other NSAIDs , COX-2 inhibitor , opioids , corticosteroid may use time study . Only subject recording average DPI 4 8 0-10 numerical rating scale least 3 day , great 9 1 day , last 5 day washout period meeting inclusion criterion randomize study . Subjects meet screen criterion randomize receive 21 day dose active dose CG100649 placebo . Antiarthritic efficacy evaluate change Western Ontario McMaster Universities ( WOMAC ) OA index complete Day 0 ( Baseline ) Days 7 , 14 , 21 , 28 , 35 . DPI functional interference ( BPI scale ) evaluate subject diary screening period study day Day 35 . Pain Relief evaluate Days 7 , 14 , 21 , 28 , 35 .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<criteria>1 . Males , age 1875 year old ; 2 . BMI 1935 kg/m2 ; 3 . Good health ; 4 . Systolic BP 90140 mmHg , diastolic BP 5090 mmHg , rest HR 4590 bpm without medication ; 5 . Clinical chemistry profile within 2x normal range without medication ; 6 . Urinalysis include urinary creatinine within 2x normal limit ; 7 . OA confirm radiograph obtain within past 20 year diagnose accord ACR guideline ; subject must qualify ACR global functional status I , II , III ( exclude IV ) KellgrenLawrence grade 1 , 2 3 ( exclude grade 0 4 ) ; 8 . Subjects must chronic pain ≥3 month OA ; 9 . Subjects must receive stable oral dos NSAIDs COX2 inhibitor least 3 day per week one month longer ; 10 . Subjects may take paracetamol ≤2g/day ) breakthrough pain ; 11 . During washout period , average daily pain intensity ( DPI ) score must 4 8 010 numerical rating scale least 3 day , great 9 1 day , last 5 day prior randomization per Baseline pain diary ; 12 . Subjects must able read , understand follow study instruction ; 13 . Subjects sexual partner must agree use double barrier contraception study period 2 month afterward . 1 . Use analgesic except study medication paracetamol ; 2 . Presence history peripheral edema within past 5 year ; 3 . History congestive heart failure ; 4 . Use chemotherapy agent history cancer within five year prior screen visit ; 5 . History bacterial viral infection require treatment antibiotic , antiviral , antiretrovirals within 3 month study ; 6 . Use drug P450 3A4 inducer inhibitor within past 30 day ; 7 . Use prescribed systemic topical medication dietary aid food know modulate drug metabolize enzyme within 14 day dose administration ; 8 . Difficulty swallow oral medication ; 9 . Subjects gout , pseudogout , inflammatory arthritis , Paget 's disease bone , chronic pain syndrome , fibromyalgia , another major joint disease ; 10 . Subjects require knee hip arthroplasty within 2 month screen anticipate need surgical procedure index joint study ; 11 . Subjects surgery affect joint within one year prior study subject prosthesis index joint ; 12 . Use systemic corticosteroid within 2 month screen , intraarticular viscosupplementation within past 6 month ; 13 . History seizure disorder ; 14 . Use antidepressant anticonvulsant reason include chronic pain within 2 month screen ; 15 . Serious psychosocial comorbidities ; 16 . Cognitive psychiatric disorder , daytime use medication could diminish compliance study procedure , include maintenance daily pain symptom diary accurate dosing study medication ; 17 . Use anticoagulant within 2 week screen ; 18 . Use medication affect pain perception ; 19 . History drug alcohol abuse within one year prior screening ; 20 . Use investigational drug within 1 month prior randomization ; 21 . Active gastrointestinal , renal , hepatic , coagulant disorder within 1 month prior randomization ; 22 . Esophageal gastroduodenal ulceration within 1 month prior randomization ; 23 . Hypersensitivity NSAIDs , sulfonamide , COX2 inhibitor , carbonic anhydrase inhibitor ; 24 . History nasal polyp , bronchospasm urticaria ; 25 . Known allergy hypersensitivity sulfa drug ; 26 . Family history significant cardiac disease ; 27 . Occult blood stool .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>COX-2</keyword>
	<keyword>carbonic anhydrase</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>anti-inflammatory</keyword>
	<keyword>Cyclooxygenase Inhibitors</keyword>
</DOC>